<DOC>
	<DOCNO>NCT01660373</DOCNO>
	<brief_summary>This single-center , open-label prospective randomize pharmacodynamic investigation two anti platelet regimens patient plan undergo PCI non-ST segment elevation acute coronary syndrome ( NSTE-ACS ) 24 hour 1 . Ticagrelor : loading dose ( 180mg ) follow maintenance dose ( 90mg bid ) 2 . Tirofiban : 0.4ug/kg/min 30min follow 0.1ug/kg/min - agent give top aspirin</brief_summary>
	<brief_title>Comparison Antiplatelet Effect Ticagrelor v Tirofiban Patients With Non-ST Elevation Acute Coronary Syndrome</brief_title>
	<detailed_description>In combination aspirin , P2Y12 receptor antagonist glycoprotein IIb/IIIa inhibitor ( GPI ) recommend drug standard dual antiplatelet regimen patient acute coronary syndrome ( 1 ) . Ticagrelor newly develop oral P2Y12 receptor inhibitor . It show faster , great consistent platelet inhibition compare previous P2Y12 receptor antagonist clopidogrel ( 2 ) also show well clinical outcome similar risk bleeding compare clopidogrel ( 3 ) .Interestingly , pharmacodynamic data study show excellent effect ticagrelor term inhibit platelet activation apparently high GPI ( 2,4 ) . Primary hypothesis : Ticagrelor comparable efficacy platelet inhibition GPI patient non-ST segment elevation acute coronary syndrome . Statistical design : non-inferiority test</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<criteria>Patients recent current ischemic symptom time randomization eligible 2 follow criterion meet : STT change indicate ischemia ; positive test biomarker indication myocardial necrosis ; one several risk factor ( age ≥60 year Previous myocardial infarction coronary artery bypass graft [ CABG ] Coronary artery disease stenosis ≥50 % least two vessel Previous ischemic stroke , transient ischemic attack , carotid stenosis least 50 % , cerebral revascularization Diabetes mellitus Peripheral arterial disease ; chronic renal dysfunction , define creatinine clearance &lt; 60 ml per minute per 1.73 m2 body surface area ) 1 . Administration fibrinolytic GP IIb/IIIa inhibitor treatment current AMI 2 . Major surgery trauma within 30 day 3 . Active bleed 4 . Previous stroke last six month 5 . Oral anticoagulant therapy 6 . Preexisting thrombocytopenia 7 . Vasculitis 8 . Hypertensive retinopathy 9 . Severe hepatic failure 10 . Severe renal failure require hemodialysis 11 . Documented allergy/intolerance contraindication tirofiban P2Y12 inhibitor 12 . Uncontrolled hypertension ( systolic diastolic arterial pressure &gt; 180 mmHg 120 , respectively , despite medical therapy ) 13 . Limited life expectancy , e.g . neoplasm , others 14 . Inability obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>tirofiban</keyword>
	<keyword>glycoprotein IIa/IIIa inhibitor</keyword>
	<keyword>P2Y12 blocker</keyword>
	<keyword>acute coronary syndrome</keyword>
</DOC>